0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editorial  | 
Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status
Tara C. Gangadhar, MD; Lynn M. Schuchter, MD
JAMA Oncology
Original Investigation  | 
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma:  A Pooled Analysis of 4 Clinical Trials
James Larkin, MD, PhD; Christopher D. Lao, MD, MPH; Walter J. Urba, MD, PhD; et al.
JAMA
Viewpoint  | 
Single Molecules Meet Genomics:  Pinpointing Precision Medicine
Xiaoliang Sunney Xie, PhD
JAMA Oncology
Research Letter  | 
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor:  Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
Helena A. Yu, MD; Shaozhou K. Tian, MD; Alexander E. Drilon, MD; et al.